ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation

(2017) Ka Lung Cheung et al.   MOLECULAR CELL

ARID1A-mutated ovarian cancers depend on HDAC6 activity

(2017) Benjamin G. Bitler et al.   NATURE CELL BIOLOGY

Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance

(2016) Richard Marcotte et al.   CELL

Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib

(2016) Rowan E. Miller et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods

(2015) Nicolette G. Alkema et al.   Scientific Reports

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

(2015) Anirudh Prahallad et al.   Cell Reports

BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo

(2014) Q. Shao et al.   CANCER RESEARCH

MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

(2014) Helge Gad et al.   NATURE

ARID1B is a specific vulnerability in ARID1A-mutant cancers

(2014) Katherine C Helming et al.   NATURE MEDICINE

Targeting bromodomains: epigenetic readers of lysine acetylation

(2014) Panagis Filippakopoulos et al.   NATURE REVIEWS DRUG DISCOVERY

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines

(2013) M Khursheed et al.   BRITISH JOURNAL OF CANCER

New insights into ovarian cancer pathology

(2012) J. Prat   ANNALS OF ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers

(2011) E-I Braicu et al.   BRITISH JOURNAL OF CANCER

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

(2010) Siân Jones et al.   SCIENCE

Differential expression analysis for sequence count data

(2010) Simon Anders et al.   GENOME BIOLOGY